The New England journal of medicine
-
Editorial Comment
SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.
-
Randomized Controlled Trial Multicenter Study
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. ⋯ A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe-critical disease, including hospitalization and death. Safety appeared to be similar to that in other phase 3 trials of Covid-19 vaccines. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.).